The ChinaBio® Partnering Forum 2014, China’s largest life science partnering event, concluded last week in Suzhou, China with record attendance of 848 delegates from 425 companies, an increase of nearly 100 delegates over 2013.

Delegates from 25 countries, representing senior leadership in multinational pharmaceutical and large biotech drug development companies, met with innovative biotech and medical technology companies, investors, and service providers from China and around the world to forge partnerships. Many companies attended specifically to initiate cross-border partnerships with China-based developers of novel technologies.

Pharmaceutical companies who brought teams to the conference included AstraZeneca, Bayer HealthCare, Bristol-Myers Squibb, Johnson & Johnson Innovation, Lilly, Novo Nordisk, and Roche. China life science companies included Beta Pharma, Eddingpharm, Hengrui and Wuxi Apptec. Attendees engaged in one-to-one partnering meetings facilitated by partneringONE®.

ChinaBio® Partnering Forum is co-organized by EBD Group, the premier partnering conference firm for the life science industry, and ChinaBio® LLC, a leading consulting and advisory firm in Shanghai.

“The continued growth of ChinaBio® Partnering Forum has established it as the best – and largest – life science event in China,” said Greg B. Scott, President and Founder of ChinaBio® LLC. “By partnering with China pharmaceutical companies, Western pharmaceutical companies gain access to the second largest pharma market in the world.  And, as some of our panelists noted, there is more and more world-class innovation coming out of China companies and the universities and institutes here.   We have only just begun to scratch the surface of the potential in China, and look forward to what we will see in our future partnering events here.”

“China represents a major healthcare market, and cross-border partnerships are increasingly attractive to drug developers,” said Florian Schoenhammer, Group Managing Director, EBD Group. “As a long-term strategy, China’s high-growth market represents unlimited potential. We expect to see increasing interest and participation in this event by international dealmakers.”

Program speakers came from a broad range of industry executives, from leading Chinese companies and service providers to global pharma.  Exclusive video coverage of ChinaBio® Partnering Forum 2014 panels is available at www.partnering360.com/insight.

Details on the 2015 edition of ChinaBio® Partnering Forum will be announced soon. The annual event attracts biotech and pharma leaders from around the world and engages delegates with one-to-one meetings, workshops and panels, exhibits, networking receptions and a gala banquet evening event. For more information, please go to www.ebdgroup.com/cbpf.

Partnering is hosted by partneringONE®, EBD Group’s sophisticated, web-based partnering system that enables event delegates to efficiently identify, meet and start partnerships with companies across the life science value chain, from large biotech and pharma companies to financiers and innovative start-ups.

Disclosure: ChinaBio® publishes ChinaBio® Today.